Prime Medicine, Inc.(PRME),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

PRME Prime Medicine, Inc.

Trading 06-17 12:49:12 EDT

3.22

+0.35

+12.02%

High3.27	Low2.87	Vol2.08M
Open2.91	D1 Closing2.87	Amplitude13.90%
Mkt Cap580.34M	Tradable Cap320.85M	Total Shares180.51M
T/O6.53M	T/O Rate2.09%	Tradable Shares99.80M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"PRME","market":"US","secType":"STK","nameCN":"Prime Medicine, Inc.","latestPrice":3.215,"timestamp":1781714939361,"preClose":2.87,"halted":0,"volume":2083278,"delay":0,"changeRate":0.12020905923344939,"floatShares":99798700,"shares":180510658,"eps":-1.237435,"marketStatus":"Trading","change":0.345,"latestTime":"06-17 12:49:12 EDT","open":2.91,"high":3.27,"low":2.8711,"amount":6527182.0501068,"amplitude":0.13899,"askPrice":3.22,"askSize":2600,"bidPrice":3.21,"bidSize":4416,"shortable":3,"etf":0,"ttmEps":-1.237435,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1781726400000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1666238400000,"exchange":"NASDAQ","adjPreClose":2.87,"preHourTrading":{"tag":"盘前","latestPrice":2.9,"preClose":2.87,"latestTime":"09:29 EDT","volume":2003,"amount":5857.7162142,"timestamp":1781702999999,"change":0.03,"changeRate":0.010453,"amplitude":0.041812},"postHourTrading":{"tag":"盘后","latestPrice":2.9,"preClose":2.87,"latestTime":"19:41 EDT","volume":6101,"amount":17472.1895,"timestamp":1781653267883,"change":0.03,"changeRate":0.010453,"amplitude":0.02547},"volumeRatio":1.717218,"impliedVol":0.8727,"impliedVolPercentile":0.1912},"requestUrl":"/m/hq/s/PRME/tweets","defaultTab":"tweets","newsList":[{"id":"2642343169","title":"Prime Medicine shareholders elect Kelly, Schenkein as Class I directors at annual meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2642343169","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642343169?lang=en_us&edition=fundamental","pubTime":"2026-06-09 04:11","pubTimestamp":1780949469,"startTime":"0","endTime":"0","summary":"Prime Medicine held its 2026 annual stockholders meeting on June 5, 2026.Stockholders backed the selection of Michael Kelly, David Schenkein, M.D. as Class I directors with terms running to the 2029 annual meeting.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Prime Medicine Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 08, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260608:nNDLbFjWZj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PRME"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640438979","title":"Prime Medicine posts corporate deck outlining prime editing pipeline focus on Wilson disease, AATD","url":"https://stock-news.laohu8.com/highlight/detail?id=2640438979","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640438979?lang=en_us&edition=fundamental","pubTime":"2026-06-02 20:37","pubTimestamp":1780403874,"startTime":"0","endTime":"0","summary":"Prime Medicine outlined a near-term push to advance prime-editing programs in Wilson disease and alpha-1 antitrypsin deficiency.Targeted PM577 IND and/or CTA filing in H1 2026, followed by Phase 1 start; initial clinical data expected in 2027.Planned PM647 IND and/or CTA filing mid-2026, followed by Phase 1 start; initial clinical data expected in 2027.CGD program PM359 positioned toward a BLA filing, with a commercial launch targeted for 2027+.Strategy includes additional partnerships, expansion beyond liver, with in vivo cystic fibrosis proof-of-concept data planned in 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Prime Medicine Inc. published the original content used to generate this news brief on June 02, 2026, and is solel","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260602:nNDL1KCfWR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PRME"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635780010","title":"Analysts Conflicted on These Healthcare Names: Kyverna Therapeutics, Inc. (KYTX), Immunome (IMNM) and Prime Medicine, Inc. (PRME)","url":"https://stock-news.laohu8.com/highlight/detail?id=2635780010","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635780010?lang=en_us&edition=fundamental","pubTime":"2026-05-13 21:40","pubTimestamp":1778679638,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Kyverna Therapeutics, Inc. (KYTX), Immunome (IMNM) and Prime Medi...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-kyverna-therapeutics-inc-kytx-immunome-imnm-and-prime-medicine-inc-prme-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-kyverna-therapeutics-inc-kytx-immunome-imnm-and-prime-medicine-inc-prme-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0128526141.USD","IMNM","HCSG","BK4585","KYTX","LABU","PRME","BK4588","XLV","BK4563","BK4137","LU0029874061.USD","XBI","BK4139","BK4581"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634292469","title":"Analysts Offer Insights on Healthcare Companies: Tenaya Therapeutics (TNYA), VistaGen Therapeutics (VTGN) and Prime Medicine, Inc. (PRME)","url":"https://stock-news.laohu8.com/highlight/detail?id=2634292469","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634292469?lang=en_us&edition=fundamental","pubTime":"2026-05-09 02:50","pubTimestamp":1778266245,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Tenaya Therapeutics (TNYA), VistaGen Therapeutics (VTGN) and Prim...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-tenaya-therapeutics-tnya-vistagen-therapeutics-vtgn-and-prime-medicine-inc-prme-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-tenaya-therapeutics-tnya-vistagen-therapeutics-vtgn-and-prime-medicine-inc-prme-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","BK4139","TNYA","HCSG","BK4588","LABU","LU0029874061.USD","PRME","VTGN","BK4585","XBI","LU0128526141.USD","XLV","BK4581","BK4137"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634092465","title":"Wedbush Keeps Their Buy Rating on Prime Medicine, Inc. (PRME)","url":"https://stock-news.laohu8.com/highlight/detail?id=2634092465","media":"TIPRANKS","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634092465?lang=en_us&edition=fundamental","pubTime":"2026-05-09 01:15","pubTimestamp":1778260559,"startTime":"0","endTime":"0","summary":"In a report released today, from Wedbush maintained a Buy rating on Prime Medicine, Inc., with a price target of $8.00. In addition to Wedbush, Pri...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/wedbush-keeps-their-buy-rating-on-prime-medicine-inc-prme-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/wedbush-keeps-their-buy-rating-on-prime-medicine-inc-prme-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PRME"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633417313","title":"Analysts’ Opinions Are Mixed on These Healthcare Stocks: Whitehawk Therapeutics (WHWK), Prime Medicine, Inc. (PRME) and Argenx Se (ARGX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2633417313","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633417313?lang=en_us&edition=fundamental","pubTime":"2026-05-08 03:10","pubTimestamp":1778181013,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Whitehawk Therapeutics (WHWK), Prime Medicine, Inc...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-whitehawk-therapeutics-whwk-prime-medicine-inc-prme-and-argenx-se-argx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-whitehawk-therapeutics-whwk-prime-medicine-inc-prme-and-argenx-se-argx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00BJJMRZ35.SGD","BK4505","BK4137","ARGX","LU0109394709.USD","BK4139","LU0128526141.USD","IE00BJT1NW94.SGD","BK4588","LABU","PRME","LU0320765992.SGD","LU1983260115.SGD","WHWK","IE00BFTCPJ56.SGD","IE0034235188.USD","IE00B2B36J28.USD","LU0029874061.USD","BK4581","IE0009355771.USD","BK4585","HCSG","IE0002141913.USD","IE00B4R5TH58.HKD","LU0889565916.HKD","LU2324357040.USD","XBI","XLV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633144740","title":"Prime Medicine Q1 EPS $(0.28) Misses $(0.25) Estimate, Sales $856.000K Miss $1.065M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2633144740","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633144740?lang=en_us&edition=fundamental","pubTime":"2026-05-07 20:17","pubTimestamp":1778156273,"startTime":"0","endTime":"0","summary":"Prime Medicine (NASDAQ:PRME) reported quarterly losses of $(0.28) per share which missed the analyst consensus estimate of $(0.25) by 12 percent. This is a 30 percent increase over losses of $(0.40) per share from the","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"11c8fbbf839f433c9d274cef5f173382","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/05/52363587/prime-medicine-q1-eps-0-28-misses-0-25-estimate-sales-856-000k-miss-1-065m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PRME","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633144443","title":"Prime Medicine Q1 net loss narrows as R&D expenses fall","url":"https://stock-news.laohu8.com/highlight/detail?id=2633144443","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633144443?lang=en_us&edition=fundamental","pubTime":"2026-05-07 20:12","pubTimestamp":1778155958,"startTime":"0","endTime":"0","summary":"Prime Medicine Q1 net loss narrows as R&D expenses fallOverviewUS gene editing biotech reported Q1 net loss narrowed from prior yearR&D expenses fell due to focus on liver programs and workforce reduc","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nL1N41K0QO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PRME"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633141296","title":"BRIEF-Prime Medicine, Inc. Q1 EPS USD -0.28","url":"https://stock-news.laohu8.com/highlight/detail?id=2633141296","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633141296?lang=en_us&edition=fundamental","pubTime":"2026-05-07 20:00","pubTimestamp":1778155250,"startTime":"0","endTime":"0","summary":"BRIEF-Prime Medicine, Inc. Q1 EPS USD -0.28\n\n\nMay 07 (Reuters) - Prime Medicine, Inc. Q1 operating expenses USD 51.51 million.\n\nQ1 income from operations USD -50.654 million\nQ1 net income USD -49.122 million","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nPLX83A1F1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PRME"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633141236","title":"Prime Medicine, Inc. Q1 Income From Operations USD -50.654 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2633141236","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633141236?lang=en_us&edition=fundamental","pubTime":"2026-05-07 20:00","pubTimestamp":1778155205,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nPLX83A1F1:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PRME"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633144834","title":"Press Release: Prime Medicine Reports First Quarter 2026 Financial Results and Provides Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2633144834","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633144834?lang=en_us&edition=fundamental","pubTime":"2026-05-07 20:00","pubTimestamp":1778155200,"startTime":"0","endTime":"0","summary":"-- On track to file IND and/or CTA for PM577 in Wilson. Disease in H1 2026 and for PM647 in AATD mid-2026;-- Continued regulatory dialogue with the FDA toward. cash of $149.2 million as of March 31, 2026, providing. Prime Medicine is currently advancing in vivo programs to cure two of the largest genetic liver diseases, Wilson Disease  and Alpha-1 Antitrypsin Deficiency . Prime Medicine expects to file an Investigational New Drug application  and/or Clinical Trial Application  for PM577 in WD in the first half of 2026 and for PM647 in AATD in mid-2026; initial clinical data from both programs are expected in 2027.Prime Medicine is also advancing an in vivo Cystic Fibrosis  program with support from the Cystic Fibrosis Foundation, and efforts to develop Prime Edited CAR-T products for hematology, immunology and oncology in partnership with Bristol Myers Squibb. Additionally, following positive proof-of-concept data from the first two patients treated in its Phase 1/2 study of PM359 for ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PRME","IND","CF","CFO","BK4588","BK4195","BK4229","BK4585","WD","CTA","BK4139","BK4093"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629831789","title":"Prime Medicine announces annual stockholders meeting via webcast","url":"https://stock-news.laohu8.com/highlight/detail?id=2629831789","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629831789?lang=en_us&edition=fundamental","pubTime":"2026-04-23 20:36","pubTimestamp":1776947779,"startTime":"0","endTime":"0","summary":"Prime Medicine schedules 2026 annual stockholder meeting in virtual format on June 5, 2026.Vote set for election of Class I directors Michael Kelly, David Schenkein.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Prime Medicine Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 23, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260423:nNDLTqJtR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PRME"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628738297","title":"Prime Medicine CFO Svetlana Ni Makhni files initial beneficial ownership statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2628738297","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628738297?lang=en_us&edition=fundamental","pubTime":"2026-04-18 08:25","pubTimestamp":1776471939,"startTime":"0","endTime":"0","summary":"Prime Medicine filed an initial beneficial ownership statement for Chief Financial Officer Svetlana Ni Makhni, dated April 16.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Prime Medicine Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 17, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260418:nNDL5cKlCx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PRME"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627865215","title":"Prime Medicine Names Svetlana Makhni CFO","url":"https://stock-news.laohu8.com/highlight/detail?id=2627865215","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627865215?lang=en_us&edition=fundamental","pubTime":"2026-04-16 21:02","pubTimestamp":1776344540,"startTime":"0","endTime":"0","summary":"Prime Medicine (PRME) said Thursday it appointed Svetlana Makhni as chief financial officer.Makhni most recently served as CFO of Marengo Therapeutics, the company said.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","PRME"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627552290","title":"Press Release: Prime Medicine Appoints Svetlana Makhni as Chief Financial Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2627552290","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627552290?lang=en_us&edition=fundamental","pubTime":"2026-04-16 20:00","pubTimestamp":1776340800,"startTime":"0","endTime":"0","summary":"CAMBRIDGE, Mass., April 16, 2026  -- Prime Medicine, Inc. , a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced the appointment of Svetlana Makhni as Chief Financial Officer . Ms. Makhni will oversee Prime Medicine's financial operations and strategy, including investor relations, financial planning and analysis, and corporate development.\"We are delighted to welcome Svetlana to Prime Medicine,\" said Allan Reine, M.D., Chief Executive Officer of Prime Medicine. \"Svetlana brings proven leadership at clinical-stage biotechnology companies, as well as deep capital markets expertise. As we prepare to enter the clinic in both Wilson Disease and Alpha-1 Antitrypsin Deficiency, her leadership will be instrumental in ensuring Prime Medicine is well positioned - both financially and strategically - to execute on the tremendous promise of Prime Editing for patients with Wilson Disease, AATD and beyond.\". Prime Medicin","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IND","BK4139","PRME","CFO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625460172","title":"Prime Medicine, Inc. (PRME) Receives a Buy from JonesTrading","url":"https://stock-news.laohu8.com/highlight/detail?id=2625460172","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625460172?lang=en_us&edition=fundamental","pubTime":"2026-04-07 04:36","pubTimestamp":1775507818,"startTime":"0","endTime":"0","summary":"JonesTrading analyst Soumit Roy maintained a Buy rating on Prime Medicine, Inc. today and set a price target of $5.00. According to TipRanks, Roy i...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/prime-medicine-inc-prme-receives-a-buy-from-jonestrading-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/prime-medicine-inc-prme-receives-a-buy-from-jonestrading-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PRME","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616328694","title":"Prime Medicine Publishes Corporate Presentation on Prime Editing Platform and Gene-Editing Pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2616328694","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616328694?lang=en_us&edition=fundamental","pubTime":"2026-03-03 21:10","pubTimestamp":1772543418,"startTime":"0","endTime":"0","summary":"Prime Medicine Inc. outlined updates on its prime editing gene-editing platform, highlighting its approach to making permanent genetic corrections without double-strand breaks or bystander edits. The company said it is prioritizing liver programs in Wilson disease  and Alpha-1 Antitrypsin Deficiency , with plans to file regulatory submissions in 2026 and begin Phase 1 clinical trials, and to report initial clinical data in 2027. Prime Medicine also described progress in its ex vivo program for chronic granulomatous disease , including plans to move toward a biologics license application following regulatory alignment, and noted ongoing work in cystic fibrosis supported by agreements with the Cystic Fibrosis Foundation, as well as an ex vivo T-cell collaboration with Bristol Myers Squibb. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accur","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260303:nNDL7BbqGb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1261432733.SGD","LU2133065610.SGD","LU1585245621.USD","LU1323610961.USD","LU1868837300.USD","IE0009355771.USD","LU0868494617.USD","BK4559","LU0096364046.USD","BK4007","LU0237698245.USD","LU1868836757.USD","BK4139","LU0882574055.USD","LU0321505439.SGD","LU1868836591.USD","LU1093756168.USD","LU2125154935.USD","IE00BSNM7G36.USD","LU1989771016.USD","BK4534","IE00BFTCPJ56.SGD","LU0225284248.USD","LU1718418525.SGD","PRME","LU1291159041.SGD","LU0225771236.USD","LU2360032135.SGD","IE00BJJMRZ35.SGD","LU0267386448.USD","BK4581","BMY","LU1670710588.SGD","IE0002141913.USD","LU1032466523.USD","LU1883839398.USD","LU0306807586.USD","LU1074936037.SGD","LU1670711123.USD","LU2242652126.USD","LU0456855351.SGD","LU0321505868.SGD","BK4588","LU0061475181.USD","LU0114720955.EUR","IE00BJT1NW94.SGD","IE00B2B36J28.USD","LU2242646821.SGD","IE00BFXG1179.USD","LU0985481810.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616328614","title":"Earnings Flash (PRME) Prime Medicine Posts 2025 Net Loss $1.35 a Share, vs. FactSet Est of $1.30 Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2616328614","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616328614?lang=en_us&edition=fundamental","pubTime":"2026-03-03 21:04","pubTimestamp":1772543095,"startTime":"0","endTime":"0","summary":"Earnings Flash (PRME) Prime Medicine Posts 2025 Net Loss $1.35 a Share, vs. FactSet Est of $1.30 Loss","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["PRME"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616340061","title":"Prime Medicine posts FY 2025 collaboration revenue of USD 4.6 million, up 2.9x","url":"https://stock-news.laohu8.com/highlight/detail?id=2616340061","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616340061?lang=en_us&edition=fundamental","pubTime":"2026-03-03 21:02","pubTimestamp":1772542928,"startTime":"0","endTime":"0","summary":"Prime Medicine posts FY 2025 collaboration revenue of USD 4.6 million, up 2.9x               Prime Medicine said its FY 2025 net loss attributable to common stockholders was USD 201.1 million, with a ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260303:nNDL40qSFf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PRME","LU1585245621.USD","LU0306806265.USD","LU1868836591.USD","LU0868494617.USD","LU1670711040.USD","LU0267386448.USD","LU1868836914.USD","LU1868837300.USD","LU1868837136.USD","LU0061475181.USD","SG9999014005.SGD","LU0306807586.USD","BK4532","BK4534","LU1868836757.USD","LU1093756325.SGD","LU2242652126.USD","LU2360032135.SGD","IE00B3QW5Z07.USD","IE00BGHQF748.EUR","LU0321505439.SGD","LU1883839398.USD","LU0314104364.USD","BMY","LU2133065610.SGD","BK4112","LU0225771236.USD","LU1989771016.USD","BK4559","IE00BJJMRZ35.SGD","IE00BSNM7G36.USD","LU0096364046.USD","IE0002141913.USD","LU1670710661.SGD","LU2095319765.USD","LU1430594728.SGD","LU2125154935.USD","LU2125154778.USD","NDAQ","IE00BFXG1179.USD","IE0009355771.USD","BK4139","LU1670710588.SGD","SG9999014021.USD","LU1718418525.SGD","IE00B64PRP62.GBP","LU0321505868.SGD","IE00BFTCPJ56.SGD","SG9999014013.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616340251","title":"BRIEF-Prime Medicine, Inc. FY EPS USD -1.35","url":"https://stock-news.laohu8.com/highlight/detail?id=2616340251","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616340251?lang=en_us&edition=fundamental","pubTime":"2026-03-03 21:00","pubTimestamp":1772542847,"startTime":"0","endTime":"0","summary":"BRIEF-Prime Medicine, Inc. FY EPS USD -1.35\n\n\nMar 03 (Reuters) - Prime Medicine, Inc. FY operating expenses USD 212.982 million.\n\nFY income from operations USD -208.35 million\nFY net income USD -201.142 million","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260303:nPLXDB84F6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PRME"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.primemedicine.com;investors.primemedicine.com","stockEarnings":[{"period":"1week","weight":-0.0035},{"period":"1month","weight":-0.0205},{"period":"3month","weight":-0.187},{"period":"6month","weight":-0.2028},{"period":"1year","weight":0.9133},{"period":"ytd","weight":-0.1729}],"compareEarnings":[{"period":"1week","weight":0.018},{"period":"1month","weight":0.0151},{"period":"3month","weight":0.1344},{"period":"6month","weight":0.1092},{"period":"1year","weight":0.245},{"period":"ytd","weight":0.1003}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address diseases by deploying gene editing technology. The company offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. It has a research collaboration with Cimeio Therapeutics to develop Prime Edited Shielded-Cell & Immunotherapy Pairs for genetic diseases, acute myeloid leukemia, and myelodysplastic syndrome. Prime Medicine, Inc. was incorporated in 2019 and is based in Cambridge, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.25,"avgChangeRate":-0.070058},{"month":2,"riseRate":0.5,"avgChangeRate":0.101559},{"month":3,"riseRate":0,"avgChangeRate":-0.224329},{"month":4,"riseRate":0.5,"avgChangeRate":-0.072402},{"month":5,"riseRate":0.5,"avgChangeRate":-0.000767},{"month":6,"riseRate":0.5,"avgChangeRate":0.190666},{"month":7,"riseRate":1,"avgChangeRate":0.211426},{"month":8,"riseRate":0,"avgChangeRate":-0.164067},{"month":9,"riseRate":0.333333,"avgChangeRate":0.111542},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.141809},{"month":11,"riseRate":0.25,"avgChangeRate":-0.086687},{"month":12,"riseRate":0.5,"avgChangeRate":0.02429}],"exchange":"NASDAQ","name":"Prime Medicine, Inc.","nameEN":"Prime Medicine, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Prime Medicine, Inc.(PRME),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Prime Medicine, Inc.(PRME) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Prime Medicine, Inc.,PRME,Prime Medicine, Inc.股票,Prime Medicine, Inc.股票老虎,Prime Medicine, Inc.股票老虎国际,Prime Medicine, Inc.行情,Prime Medicine, Inc.股票行情,Prime Medicine, Inc.股价,Prime Medicine, Inc.股市,Prime Medicine, Inc.股票价格,Prime Medicine, Inc.股票交易,Prime Medicine, Inc.股票购买,Prime Medicine, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Prime Medicine, Inc.(PRME),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Prime Medicine, Inc.(PRME) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction